Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

Jeong, Nan Hee; Lee, Nak Woo; Woo, Mi Kyung; Kim, Hee Jin

doi:10.1007/s12272-009-1311-1

Cited by 7 publications

(2 citation statements)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, as shown in Table , our findings for anti‐HPV E6, E7, and L1 antibodies are consistent with previous observations in terms of increased seroprevalence in cervical lesions . Our results also show that the frequencies of antibodies against HPV E6 and E7 (in types 16 and 18) are higher in cervical cancer than in CIN stages.…”

Section: Discussionsupporting

confidence: 92%

“…Overall, as shown in Table S2, our findings for anti-HPV E6, E7, and L1 antibodies are consistent with previous observations in terms of increased seroprevalence in cervical lesions. [27][28][29][30][31][32][33][34] Our results also show that the frequencies of antibodies against HPV E6 and E7 (in types 16 and 18) are higher in cervical cancer than in CIN stages. Similar trends in the seroprevalence of antibodies against HPV E6 and E7 antigen in Korean women have been reported previously.…”

Section: Comparison With Previous Studiessupporting

confidence: 59%

See 1 more Smart Citation

Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Sero‐epidemiological studies of human papillomavirus (HPV) have been undertaken over the last two decades. In this study, the prevalences of nine serum antibodies (anti‐E6, E7 and L1 antibodies of HPV types 16, 18, and 58) were evaluated in normal (control) Korean women and women with cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III, and cervical cancer. The frequencies of all types of anti‐HPV antibodies were higher in the CIN stages and cervical cancer than in normal women, and those of anti‐HPV16 E6 and E7, anti‐HPV18 E6 and E7, and anti‐HPV58 E7 antibodies were higher in the cervical cancer group than in the CIN stages. The frequencies of antibodies against HPV16, 18, and 58 E7 tended to increase with increasing severity of cervical lesions. However, there were few differences in the frequencies of antibodies against the L1 antigens of HPV16, 18 and 58 in cervical cancer versus CIN stages. The anti‐HPV antibodies were detected in 26.5% of normal, 46.3% of CIN I, 62.5% of CIN II, 51.6% of CIN III, and 75% of cancers when any of the nine antigens was used as a criterion. Correlations between HPV DNA positivity and seropositivity for anti‐HPV E6, E7, or L1 antibodies were found only in HPV16 DNA‐positive cervical cancers for anti‐HPV16 E6 and L1 antibodies. In addition, strong positive correlations in seropositivity were found between anti‐HPV16 E7 and anti‐HPV58 E7 antibodies, and between anti‐HPV18 E6 and anti‐HPV58 E6 antibodies. These findings should advance global profiling of the seroprevalences of antibodies against HPV antigens.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Comparison With Previous Studiessupporting

confidence: 59%

Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae

et al. 2009

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) types 16 and 18 are the main targets in the field of prophylactic vaccines for preventing cervical cancer. L1 protein, the major capsid protein of HPV, selfassembles into virus-like particles (VLP), which are the major component of prophylactic vaccines. To obtain highly purified L1 protein, contaminants must be removed by several chromatography steps. However, this requires a great deal of time and labor, and results in loss of large amounts of the target protein. Therefore, we have sought to develop an efficient method for removing contaminants prior to chromatography during the purification of HPV18 L1 protein from Saccharomyces cerevisiae. For this purpose the contaminating proteins were removed by an ammonium sulfate precipitation step and further removed by a removal of precipitated contaminants step. Purification of the L1 protein by chromatography was significantly improved by the removal of precipitated contaminants step. In the present work we developed two one-step chromatography methods (heparin and cation-exchange chromatography), and HPV18 L1 proteins purified by both methods self-assembled into VLP. The two chromatographic purification methods are simpler and more convenient than previous methods and are widely applicable to work with VLPs.

show abstract

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

Purpose Global data on human papillomavirus serological and DNA prevalence are essential to optimize HPV prophylactic vaccination strategies. Methods We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV types 16, 18, 6 and 11. Results One hundred-seventeen studies were included; participants’ ages ranged from several hours to over 90 years. HPV 16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than men, and peaked around ages 25-40 years. HPV 18 seroprevalence was generally lower than HPV 16 with a later age peak. Data were limited for HPV 6 and 11, which both peaked at ages similar to HPV 18. In 9-26 year-old females, HPV 16 seroprevalence ranged from 0-31% in North America, 21-30% in Africa, 0-23% in Asia/Australia, 0-33% in Europe, and 13-43% in Central and South America. HPV 16/18 DNA prevalence peaked 10-15 years before corresponding HPV 16/18 antibody prevalence. Conclusions Females within the HPV-vaccine eligible age group (9-26 years) had a range of dual HPV 16 DNA and serology negativity from 81-87%, whereas 90-98% were HPV 16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

show abstract

Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions

Cited by 7 publications

References 26 publications

Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer

Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer

A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Contact Info

Product

Resources

About